PMID- 17309752
OWN - NLM
STAT- MEDLINE
DCOM- 20070501
LR  - 20220330
IS  - 1083-4389 (Print)
IS  - 1083-4389 (Linking)
VI  - 12
IP  - 2
DP  - 2007 Apr
TI  - Results from the pediatric European register for treatment of Helicobacter pylori 
      (PERTH).
PG  - 150-6
AB  - BACKGROUND AND AIM: Data on the eradication treatment for childhood Helicobacter 
      pylori are scanty. A register was established on the European Society for 
      Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) website to collect 
      data on treatment performed by European pediatricians to ascertain what is 
      practiced in the field. SUBJECTS: From January 2001 to December 2002, information 
      on 597 children were entered by 23 European Centers, but only data of 518 treated 
      children were completed and analyzed (86.7%, 262 male subjects, median age 9 
      years, range 1-14). According to their nationality, 226 children were from 
      Southern Europe, 132 from Eastern Europe, 68 from Western Europe, and 4 from 
      northern Europe, 68 from North Africa, and 20 from Asia. At endoscopy, 454 
      children had gastritis and 64 had ulcer (12.3%). Antibiotic sensitivity, tested 
      in 361 cases, revealed 18% clarithromycin-resistant and 19% 
      metronidazole-resistant H. pylori strains. RESULTS: Treatment was performed for 1 
      week in 388 and for 2 weeks in 130 children. Antibiotics were associated with 
      proton pump inhibitors (PPI) in 345 and with bismuth in 121 children. Triple 
      therapy was given to 485 children, dual therapy to 26, quadruple to 7. Follow-up 
      data, by (13)C-Urea-Breath Test or histology or both, were available for 480 
      children. Overall eradication rate was 65.6%, significantly higher in children 
      with ulcer (79.7%) than without (63.9%, p = .001). When given as first treatment, 
      bismuth-containing triple therapies were more efficacious than PPI-containing 
      ones (77% versus 64%, p = .02, OR 1.88, 95% CI 1.1-3.3). Twenty-seven different 
      treatment regimens were used, but only six were administered to at least 18 
      children (range 18-157). There was no difference between treatments given for 1 
      or 2 weeks, or given as first or second therapies. CONCLUSION: European 
      pediatricians entering data in the register used 27 different regimens. 
      Bismuth-containing therapies resulted in higher eradication rate. 
      Omeprazole-containing triple therapies were the most used although their efficacy 
      was low. Therapies recommended for adults do not appear to be suitable for 
      children.
FAU - Oderda, Giuseppina
AU  - Oderda G
AD  - University of Piemonte Orientale, Novara, Italy. oderda@med.unipmn.it
FAU - Shcherbakov, Peter
AU  - Shcherbakov P
FAU - Bontems, Patrick
AU  - Bontems P
FAU - Urruzuno, Pedro
AU  - Urruzuno P
FAU - Romano, Claudio
AU  - Romano C
FAU - Gottrand, Frederic
AU  - Gottrand F
FAU - Gomez, M Jose Martinez
AU  - Gomez MJ
FAU - Ravelli, Alberto
AU  - Ravelli A
FAU - Gandullia, Paolo
AU  - Gandullia P
FAU - Roma, Elefteria
AU  - Roma E
FAU - Cadranel, Sami
AU  - Cadranel S
FAU - De Giacomo, Costantino
AU  - De Giacomo C
FAU - Canani, Roberto Berni
AU  - Canani RB
FAU - Rutigliano, Vincenzo
AU  - Rutigliano V
FAU - Pehlivanoglu, Ender
AU  - Pehlivanoglu E
FAU - Kalach, Nicolas
AU  - Kalach N
FAU - Roggero, Paola
AU  - Roggero P
FAU - Celinska-Cedro, Danuta
AU  - Celinska-Cedro D
FAU - Drumm, Brendan
AU  - Drumm B
FAU - Casswall, Thomas
AU  - Casswall T
FAU - Ashorn, Marja
AU  - Ashorn M
FAU - Arvanitakis, Sanda Nousia
AU  - Arvanitakis SN
CN  - European Pediatric Task Force on Helicobacter pylori
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Antacids)
RN  - H1250JIK0A (Clarithromycin)
RN  - KG60484QX9 (Omeprazole)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Adolescent
MH  - Antacids/therapeutic use
MH  - Bismuth/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Europe/epidemiology
MH  - Female
MH  - Helicobacter Infections/*drug therapy/*epidemiology/microbiology
MH  - Helicobacter pylori/*drug effects/pathogenicity
MH  - Humans
MH  - Infant
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Omeprazole/therapeutic use
MH  - Registries
MH  - Treatment Outcome
EDAT- 2007/02/21 09:00
MHDA- 2007/05/02 09:00
CRDT- 2007/02/21 09:00
PHST- 2007/02/21 09:00 [pubmed]
PHST- 2007/05/02 09:00 [medline]
PHST- 2007/02/21 09:00 [entrez]
AID - HEL485 [pii]
AID - 10.1111/j.1523-5378.2007.00485.x [doi]
PST - ppublish
SO  - Helicobacter. 2007 Apr;12(2):150-6. doi: 10.1111/j.1523-5378.2007.00485.x.